Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Sep 6 2022 | Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News In The News Industry Read More Jun 22 2022 | Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil Industry News In The News Industry Read More May 20 2022 | Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil Industry News In The News Industry Read More Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More Apr 22 2022 | Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page Next › Last page Last »
Sep 6 2022 | Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News In The News Industry Read More
Jun 22 2022 | Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil Industry News In The News Industry Read More
May 20 2022 | Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil Industry News In The News Industry Read More
Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More
Apr 22 2022 | Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers Industry News In The News Industry Read More